Literature DB >> 22285289

Scientific tools, fake treatments, or triggers for psychological healing: how clinical trial participants conceptualise placebos.

Felicity L Bishop1, Eric E Jacobson, Jessica R Shaw, Ted J Kaptchuk.   

Abstract

Placebos are an essential tool in randomised clinical trials, where they are used to control for bias and contextual healing effects. Placebos and their effects are also studied from multiple diverse perspectives, but the perspectives of placebo recipients are seldom considered. Research shows that people form cognitive and affective representations of active treatments such as medicines, and that they use these representations to guide their behaviour; it seems reasonable to suggest that people might also think about and develop representations of placebos. We adopted a qualitative approach to examine in detail how participants in one RCT, conducted in the USA, conceptualised placebos. 12 people were interviewed 3 times each, at the start, middle, and end of a trial of placebo effects and acupuncture for Irritable Bowel Syndrome (IBS). The interview data were analysed inductively and we identified four ways in which the participants conceptualised placebos: placebos are necessary for research; placebo effects are fake; placebo acupuncture is not real acupuncture; placebos have real effects mediated by psychological mechanisms. Participants' conceptualisations of placebos were dynamic and situated in a broader psychological and socio-cultural context. Seeing placebo effects as legitimate seemed to be facilitated by having more holistic models of healing, viewing IBS as psychological, and seeing treatment as multifactorial. However, some participants maintained a negative view of placebo effects (e.g. as illusions) that was apparently inconsistent with their other beliefs (e.g. in mind-body healing mechanisms). This may indicate a dominance of negative discourses around placebos at a socio-cultural level. Negative views of placebos are inconsistent with evidence that placebo treatments can have positive effects on symptoms. RCT participants should be informed about potential benefits of placebo treatments to avoid misunderstandings and unease. Future work should improve methods of providing participants with full accurate information about placebos and their effects. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285289      PMCID: PMC3288621          DOI: 10.1016/j.socscimed.2011.11.020

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  40 in total

1.  Attitudes of patients with schizophrenia toward placebo-controlled clinical trials.

Authors:  Martina Hummer; Roswitha Holzmeister; Georg Kemmler; Ursula Eder; Alex Hofer; Ilsemarie Kurzthaler; Maria Oehl; Elisabeth Weiss; W Wolfgang Fleischhacker
Journal:  J Clin Psychiatry       Date:  2003-03       Impact factor: 4.384

2.  Meta-analysis of sleep changes in control groups of insomnia treatment trials.

Authors:  Lynda Bélanger; Annie Vallières; Hans Ivers; Vincent Moreau; Gilles Lavigne; Charles M Morin
Journal:  J Sleep Res       Date:  2007-03       Impact factor: 3.981

Review 3.  Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

Authors:  Mark Sinyor; Anthony J Levitt; Amy H Cheung; Ayal Schaffer; Alex Kiss; Yekta Dowlati; Krista L Lanctôt
Journal:  J Clin Psychiatry       Date:  2010-01-26       Impact factor: 4.384

4.  Double-blind versus deceptive administration of a placebo.

Authors:  I Kirsch; L J Weixel
Journal:  Behav Neurosci       Date:  1988-04       Impact factor: 1.912

5.  False hopes and best data: consent to research and the therapeutic misconception.

Authors:  P S Appelbaum; L H Roth; C W Lidz; P Benson; W Winslade
Journal:  Hastings Cent Rep       Date:  1987-04       Impact factor: 2.683

6.  Lay public's understanding of equipoise and randomisation in randomised controlled trials.

Authors:  E J Robinson; C E P Kerr; A J Stevens; R J Lilford; D A Braunholtz; S J Edwards; S R Beck; M G Rowley
Journal:  Health Technol Assess       Date:  2005-03       Impact factor: 4.014

Review 7.  Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Eur Neuropsychopharmacol       Date:  2008-09-26       Impact factor: 4.600

8.  Placebos without deception: a randomized controlled trial in irritable bowel syndrome.

Authors:  Ted J Kaptchuk; Elizabeth Friedlander; John M Kelley; M Norma Sanchez; Efi Kokkotou; Joyce P Singer; Magda Kowalczykowski; Franklin G Miller; Irving Kirsch; Anthony J Lembo
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

9.  Reactions to treatment debriefing among the participants of a placebo controlled trial.

Authors:  Zelda Di Blasi; Fay Crawford; Colin Bradley; Jos Kleijnen
Journal:  BMC Health Serv Res       Date:  2005-04-22       Impact factor: 2.655

10.  Prescribing "placebo treatments": results of national survey of US internists and rheumatologists.

Authors:  Jon C Tilburt; Ezekiel J Emanuel; Ted J Kaptchuk; Farr A Curlin; Franklin G Miller
Journal:  BMJ       Date:  2008-10-23
View more
  21 in total

1.  Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities.

Authors:  Jill A Fisher; Marci D Cottingham; Corey A Kalbaugh
Journal:  Soc Sci Med       Date:  2014-08-19       Impact factor: 4.634

2.  Lifestyle Vaccines and Public Health: Exploring Policy Options for a Vaccine to Stop Smoking.

Authors:  Anna Wolters; Guido de Wert; Onno C P van Schayck; Klasien Horstman
Journal:  Public Health Ethics       Date:  2016-03-14       Impact factor: 1.940

3.  Placebo disclosure does not result in negative changes in mood or attitudes towards health care or the provider.

Authors:  Joel E Bialosky; Michael E Robinson
Journal:  J Man Manip Ther       Date:  2017-03-09

4.  Experiences of Patients Taking Conditioned Open-Label Placebos for Reduction of Postoperative Pain and Opioid Exposure After Spine Surgery.

Authors:  Valerie Hruschak; K Mikayla Flowers; Megan Patton; Victoria Merchantz; Emily Schwartz; Robert Edwards; Ted Kaptchuk; James Kang; Michelle Dossett; Kristin Schreiber
Journal:  Int J Behav Med       Date:  2022-08-01

5.  What are the keys to a longer, happier life? Answers from five decades of health psychology research.

Authors:  Blair T Johnson; Rebecca L Acabchuk
Journal:  Soc Sci Med       Date:  2017-11-04       Impact factor: 4.634

6.  Informed consent and placebo effects: a content analysis of information leaflets to identify what clinical trial participants are told about placebos.

Authors:  Felicity L Bishop; Alison E M Adams; Ted J Kaptchuk; George T Lewith
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

7.  Research on placebo analgesia is relevant to clinical practice.

Authors:  Charles W Gay; Mark D Bishop
Journal:  Chiropr Man Therap       Date:  2014-02-03

8.  Patients' attitudes about the use of placebo treatments: telephone survey.

Authors:  Sara Chandros Hull; Luana Colloca; Andrew Avins; Nancy P Gordon; Carol P Somkin; Ted J Kaptchuk; Franklin G Miller
Journal:  BMJ       Date:  2013-07-02

9.  When and why placebo-prescribing is acceptable and unacceptable: a focus group study of patients' views.

Authors:  Felicity L Bishop; Lizzi Aizlewood; Alison E M Adams
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

10.  Participants' Treatment Perspectives on a Clinical Trial on the Use of Extended-Release Naltrexone for Substance Use Disorders: Considerations for Future Clinical Research.

Authors:  Geoff Bardwell; Kaitlyn Jaffe; P Todd Korthuis; Lindsey Richardson
Journal:  J Addict Med       Date:  2021 Sep-Oct 01       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.